Uterine Cervical Neoplasm

Dietary Modification

Radiation Toxicity

Gastrointestinal Complication

Dietary intervention will consist on a low residue diet: 20% kcal from fat, 5g lactose/day, 20g fiber/day (5g from insoluble fiber).
Dietary intervention will be adapted to the patient's individual requirements, according to the presence of comorbidities or renal deterioration.
No comorbidities. Energy: 20-30 kcal/kg of body weight/day. Protein: 1.3 g/kg of body weight/day.
Comorbidities (diabetes, hypertension), or geriatric patient. Energy: 25-30 kcal/kg of body weight/day. Protein: 1.5 g/kg of body weight/day.
Renal deterioration. Energy: 30-35 kcal/kg of body weight/day. Protein: 1 g/kg of body weight/day. Sodium: 2000-2300 mg/day. Potassium: 1900-2730 mg/day. Phosphorus: 800-1000 mg/day.

Dietary modification

National Cancer Institute of Mexico

Effect of a Low Residue Diet in Comparison to the Dietetic Recommendations From the INCan in Cervical Cancer Patients

Effect of a Low Residue Diet in Comparison to the Dietary Recommendations From the INCan: A Randomized Clinical Trial to Assess Malnutrition, Gastrointestinal Toxicity and Quality of Life of Advanced Cervical Cancer Patients (IB2-IVA)

Nutritional status will be evaluated by the complete nutritional assessment described above.

Dr. Lucely Cetina Pérez

MD, MSc.

National Institute of Cancerología

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

Ulcerative Colitis

Capsule Endoscopy

Sheari-Zedek Medical Center

Puerta de Hierro

Evaluation of PillCam IBD Capsule Endoscopy System in Visualization of Lesions in the Colon Indicative of Ulcerative Colitis Disease

Medtronic - MITG

Active medications - Rectal tacrolimus made as an ointment at a concentration of 0.5mg/ml 3mls will be applied rectally twice a day

Placebo 3ml applied rectally twice a day. Identical to Interventional agent expect for the lack of tacrolimus

Rectal tacrolimus made as an ointment at a concentration of 0.5mg/ml with 3 mls will be applied rectally twice a day

Rectal tacrolimus

Placebo

Liverpool Hospital

Royal Brisbane and Women's Hospital

Royal Adelaide Hospital

Centre for IBD, Fremantle Hospital

Rectal Tacrolimus in the Treatment of Resistant Ulcerative Proctitis

A Multi-centre Double Blind Randomised Placebo-controlled Study of the Use of Rectal Tacrolimus in the Treatment of Resistant Ulcerative Proctitis

Clinical response (Mayo Score) of resistant ulcerative proctitis after 8 weeks of rectal tacrolimus therapy

Remission rates (Mayo Score) of resistant ulcerative proctitis after 8 weeks of rectal tacrolimus

Effect of rectal tacrolimus on mucosal healing after 8 weeks of therapy

Changes in the modified Mayo Score between tacrolimus and control groups over 8 weeks of therapy

Changes in quality of life by the Inflammatory Bowel Disease Questionnaire (IBDQ) between tacrolimus and control groups over 8 weeks of therapy

Safety and tolerability of rectal tacrolimus over 8 weeks of therapy

Changes in cytokine expression in mucosal biopsies following rectal tacrolimus therapy

proctitis/בחילה

Effect of a Low Residue Diet in Comparison to the Dietetic Recommendations From the INCan in Cervical Cancer Patients

Evaluation of PillCam IBD Capsule Endoscopy System in Visualization of Lesions in the Colon Indicative of Ulcerative Colitis Disease

Rectal Tacrolimus in the Treatment of Resistant Ulcerative Proctitis

המאגר השלם ביותר של צמחי מרפא המגובה על ידי המדע